Dignitana AB Publishes Q2 2023 Interim Report
15 percent revenue growth driven by improved utilization
Financial highlights Q2 2023
- Net sales amounted to 21.1 MSEK (18.3), an increase of 15 percent over the same period in 2022
- Operating result amounted to -4.7 MSEK (+0.1).
- Net result after financial items amounted to -4.7 MSEK (-0.2).
- Earnings per share were-0.07 SEK (0.00).
- Cash Balance amounted to 5.4 MSEK (7.3).
- Average Daily Treatment Revenue (ADTR)* was 241 TSEK (201), an increase of 20 percent over the same period in 2022.
Business highlights during the period
- Dignitana announced a proposal for Local Coverage Determination of scalp cooling therapy for seven states in the Southeastern United States.
- Dignitana exhibited at the Oncology Nursing Congress in San Antonio, Texas.
- Dignitana co-sponsored a scalp cooling session at the Multinational Association of Supportive Care in Cancer conference in Japan along with exhibiting at the conference.
- In May Dignitana published the Annual Report for 2022.
- Dignitana’s Annual General Meeting was held on 25 May 2023.
Business highlights after the period
- Five year follow up results from the DigniCap pivotal trial were published in the Journal of Supportive Care in cancer demonstrating both safety and efficacy in the first long term study of scalp cooling.
- Dignitana announced that the partnership with oneservice has expanded to now provide service in the field to DigniCap customers in Europe.
- DigniCap Delta was introduced to customers in Mexico by Celeritas, DigniCap’s longtime partner there.
Key Figures
| DIGNITANA GROUP | Q2 2023 | Q2 2022 | Q1-Q2 2023 | Q1-Q2 2022 | Full Year 2022 |
| Net sales, TSEK | 21,089 | 18,284 | 42,578 | 34,148 | 72,995 |
| Total revenues, TSEK | 23,159 | 24,067 | 44,764 | 40,777 | 83,849 |
| Net profit after financial items, TSEK | -4,662 | -232 | -8,600 | -6,740 | -22,396 |
| Cash and bank balances, TSEK | 5,423 | 7,312 | 5,423 | 7,312 | 8,869 |
| Earnings per share before and after dilution, SEK | -0.07 | 0.00 | -0.12 | -0.10 | -0.34 |
| Average Daily Treatment revenue*, TSEK | 241 | 201 | 242 | 190 | 203 |
*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
“With a focus on device utilization, our circular business model creates, captures and delivers value by redeploying underutilized devices and thus maximizing revenue potential and fostering sustainable use of assets.” - Catarina Löwenadler, CEO Dignitana AB
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-08-2023 08:09 CET.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
Tags: